Press Releases

08.01.2019
Iveric Bio Reports Second Quarter 2019 Financial and Operating Results
07.25.2019
Iveric Bio to Report Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019
07.23.2019
Iveric Bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program
06.17.2019
Iveric Bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases
05.08.2019
Iveric Bio Reports First Quarter 2019 Financial and Operating Results
05.01.2019
Iveric Bio to Report First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019
04.16.2019
Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Inherited Retinal Diseases and Changes Name to IVERIC bio
04.11.2019
Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases
03.14.2019
Ophthotech to Present at the Alliance for Regenerative Medicine’s (ARM) 7th Annual Cell & Gene Therapy Investor Day
03.06.2019
Ophthotech to Present at the Cowen and Company 39th Annual Health Care Conference